Arvinas Target of Unusually Large Options Trading (NASDAQ:ARVN)

Arvinas, Inc. (NASDAQ:ARVN) was the target of some unusual options trading on Wednesday. Investors purchased 5,428 call options on the stock. This represents an increase of approximately 155% compared to the average daily volume of 2,130 call options.

Insider Buying and Selling at Arvinas

In other news, insider Ian Taylor sold 9,020 shares of the firm’s stock in a transaction that occurred on Monday, February 24th. The shares were sold at an average price of $16.71, for a total transaction of $150,724.20. Following the transaction, the insider now directly owns 159,121 shares of the company’s stock, valued at approximately $2,658,911.91. This trade represents a 5.36 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO John G. Houston sold 31,338 shares of the business’s stock in a transaction that occurred on Monday, February 24th. The shares were sold at an average price of $16.72, for a total value of $523,971.36. Following the completion of the sale, the chief executive officer now owns 1,157,480 shares of the company’s stock, valued at $19,353,065.60. The trade was a 2.64 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 41,572 shares of company stock worth $695,030 over the last 90 days. Company insiders own 5.23% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. JPMorgan Chase & Co. boosted its position in Arvinas by 18.7% during the third quarter. JPMorgan Chase & Co. now owns 2,329,303 shares of the company’s stock worth $57,371,000 after purchasing an additional 367,343 shares in the last quarter. Baker BROS. Advisors LP purchased a new stake in Arvinas in the 3rd quarter worth $9,989,000. SG Americas Securities LLC raised its position in Arvinas by 228.8% during the fourth quarter. SG Americas Securities LLC now owns 32,424 shares of the company’s stock worth $622,000 after acquiring an additional 22,564 shares during the period. Wasatch Advisors LP lifted its holdings in Arvinas by 58.3% during the third quarter. Wasatch Advisors LP now owns 435,943 shares of the company’s stock valued at $10,737,000 after purchasing an additional 160,510 shares in the last quarter. Finally, Barclays PLC raised its position in shares of Arvinas by 198.9% during the 3rd quarter. Barclays PLC now owns 121,699 shares of the company’s stock worth $2,998,000 after purchasing an additional 80,984 shares during the last quarter. Institutional investors and hedge funds own 95.19% of the company’s stock.

Analyst Upgrades and Downgrades

ARVN has been the topic of a number of recent research reports. BTIG Research initiated coverage on shares of Arvinas in a research note on Tuesday, December 10th. They set a “buy” rating and a $69.00 price objective on the stock. Stifel Nicolaus cut their price target on Arvinas from $63.00 to $51.00 and set a “buy” rating on the stock in a report on Wednesday, February 12th. Oppenheimer boosted their price target on Arvinas from $40.00 to $45.00 and gave the stock an “outperform” rating in a research report on Wednesday, February 12th. Barclays dropped their price objective on Arvinas from $48.00 to $32.00 and set an “overweight” rating on the stock in a research report on Monday, February 3rd. Finally, Wedbush restated an “outperform” rating and issued a $57.00 target price on shares of Arvinas in a research note on Tuesday, February 11th. Twelve equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus target price of $60.00.

Arvinas Price Performance

NASDAQ ARVN opened at $18.06 on Friday. The company has a fifty day moving average of $18.25 and a 200 day moving average of $22.50. The company has a market capitalization of $1.24 billion, a PE ratio of -6.52 and a beta of 1.95. Arvinas has a 1 year low of $15.53 and a 1 year high of $49.76.

Arvinas (NASDAQ:ARVN) last posted its earnings results on Tuesday, February 11th. The company reported ($0.63) EPS for the quarter, topping the consensus estimate of ($1.07) by $0.44. Arvinas had a negative return on equity of 33.75% and a negative net margin of 75.51%. During the same quarter last year, the business earned ($2.53) EPS. Research analysts expect that Arvinas will post -3.81 earnings per share for the current year.

Arvinas Company Profile

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body’s own natural protein disposal system to degrade and remove disease-causing proteins.